<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patisiran: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patisiran: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Patisiran: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="118992" href="/d/html/118992.html" rel="external">see "Patisiran: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51792669"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Onpattro</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53644607"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Onpattro</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51765661"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Transthyretin Small Interfering Ribonucleic Acid (siRNA) Agent</li></ul></div>
<div class="block doa drugH1Div" id="F51776172"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Safety: </b>Concomitant vitamin A supplementation is advised at appropriate recommended daily allowances during therapy due to patisiran-associated decreases in serum vitamin A concentrations. <b>Premedication: </b>At least 60 minutes prior to administration of patisiran, premedicate with a corticosteroid, acetaminophen, an H<sub>1</sub> blocker, and an H<sub>2</sub> blocker to reduce the risk of infusion-related reactions; see “Premedications” below.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee5ba770-b8c7-4cef-b7ad-dfcf600b532c">Polyneuropathy of hereditary-transthyretin mediated amyloidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polyneuropathy of hereditary-transthyretin mediated amyloidosis</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;100 kg (Actual body weight): <b>IV: </b>0.3 mg/kg once every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">≥100 kg (Actual body weight): <b>IV:</b> 30 mg once every 3 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Within 3 days of missed dose: Administer missed dose as soon as possible, then continue dosing according to original schedule.</p>
<p style="text-indent:-2em;margin-left:4em;">More than 3 days after missed dose: Administer missed dose as soon as possible, then continue dosing every 3 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedication:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Premedicate at least 60 minutes prior to each patisiran administration with an IV corticosteroid (eg, dexamethasone 10 mg or equivalent), oral acetaminophen (500 mg), an IV H<sub>1</sub> blocker (eg, diphenhydramine 50 mg or equivalent), and an IV H<sub>2</sub> blocker (eg, famotidine 20 mg or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29972753','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29972753','lexi-content-ref-Manu.1'])">Ref</a></span>). An oral equivalent may be administered for premedications not tolerated or not available IV. Additional or higher doses of one or more premedications may be necessary. For patients tolerating patisiran infusions but with adverse effects due to corticosteroid premedication, may reduce IV dexamethasone (or equivalent doses of another corticosteroid) by 2.5 mg increments to a minimum dose of 5 mg.</p></div>
<div class="block dora drugH1Div" id="F51776174"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 to &lt;90 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F51776175"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (bilirubin ≤1 x ULN and AST &gt;1 x ULN or bilirubin &gt;1 to 1.5 x ULN): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F51792845"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Infusion-related reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate:</i> Consider slowing or interrupting the infusion and resuming at a slower infusion rate when symptoms have resolved; consider additional or higher doses of premedication during subsequent infusions to reduce infusion-related reactions risk.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Serious or life-threatening</i>: Discontinue therapy and do not readminister.</p></div>
<div class="block doe drugH1Div" id="F51776173"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51768916"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (3%; including complete atrioventricular block)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Vertigo (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7%), muscle spasm (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (3%), dry eye syndrome (5%), vitreous opacity (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (7%), dyspnea (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Vitamin A deficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p></div>
<div class="block coi drugH1Div" id="F51765664"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Severe hypersensitivity (eg, anaphylaxis) to patisiran or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F51776160"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions (IRR) have been reported, with a majority occurring within the first 2 infusions and the frequency decreasing with additional infusions. Common symptoms included abdominal, back or chest pain, dyspnea, facial edema, flushing, headache, nausea, rash, and tachycardia; severe hypotension and syncope have also been reported. Premedicate with a corticosteroid, acetaminophen, and antihistamines (H<sub>1</sub> and H<sub>2</sub> blockers).</p>
<p style="text-indent:-2em;margin-left:4em;">• Reduced vitamin A levels: A decrease in serum vitamin A has been reported with patisiran treatment. Supplement the recommended daily allowance (RDA) of vitamin A during treatment. Do not administer doses higher than the RDA; serum vitamin A levels do not reflect the total vitamin A in the body. If ocular symptoms such as night blindness develop, refer the patient to an ophthalmologist.</p></div>
<div class="block foc drugH1Div" id="F51792670"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Onpattro: 10 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F51792668"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51805638"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Onpattro Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $2,348.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53644608"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Onpattro: 10 mg/5 mL (5 mL)</p></div>
<div class="block adm drugH1Div" id="F51776177"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Following dilution and filtering, administer via an ambulatory infusion pump through a dedicated free-flowing DEHP-free line. Use a DEHP-free infusion set containing a 1.2 micron polyethersulfone in-line infusion filter. Infuse over ~80 minutes, with an initial infusion rate of ~1 mL/minute for 15 minutes, then increase to ~3 mL/minute for the remainder of the infusion. May extend duration of infusion &gt;80 minutes to manage or prevent infusion-related reactions. After infusion is complete, flush IV administration set with NS. Monitor infusion site for infiltration and manage suspected extravasation using local standard practice for nonvesicants.</p></div>
<div class="block use drugH1Div" id="F51765663"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Polyneuropathy of hereditary-transthyretin mediated amyloidosis:</b> Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.</p></div>
<div class="block cyt drugH1Div" id="F51772091"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F51772088"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F51776158"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Patisiran decreases serum concentrations of vitamin A, which is required for normal fetal development. The effects to the fetus of maternal vitamin A supplementation during patisiran therapy, or the effects to the fetus of reducing maternal serum transthyretin, are not known.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to patisiran is ongoing. Health care providers are encouraged to enroll females exposed to patisiran during pregnancy in the Pregnancy Registry (877-256-9526 or <a class="__cf_email__" data-cfemail="ef8e838196838e829f9d8a88818e818c969f9d80889d8e82af869e99868ec18c8082" href="/cdn-cgi/l/email-protection">[email protected]</a>). Pregnant women may also register themselves.</p></div>
<div class="block brc drugH1Div" id="F51776159"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if patisiran is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother</p></div>
<div class="block mop drugH1Div" id="F51776179"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Infusion-related reactions; ocular symptoms indicative of vitamin A deficiency (eg, night blindness)</p></div>
<div class="block pha drugH1Div" id="F51776164"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Patisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of mutant and wild-type transthyretin (TTR) mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues. Serum TTR is a carrier of retinol binding protein, which is involved in the transport of vitamin A in the blood.</p></div>
<div class="block phk drugH1Div" id="F51776165"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: 10 to 14 days (mean serum TTR reduced by ~80%)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 0.26 ± 0.2 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Plasma protein: ≤2.1% (albumin and human alpha1-acid glycoprotein)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: By nucleases to nucleotides of various lengths</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3.2 ± 1.8 days</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: &lt;1% as unchanged drug</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52003659"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Onpattro</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29972753">
<a name="29972753"></a>Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. <i>N Engl J Med</i>. 2018;379(1):11-21. doi:10.1056/NEJMoa1716153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/patisiran-drug-information/abstract-text/29972753/pubmed" id="29972753" target="_blank">29972753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Onpattro.1">
<a name="Onpattro.1"></a>Onpattro (patisiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals Inc; January 2023.</div>
</li>
<li>
<div class="reference">
                  Onpattro (patisiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Onpattro.3">
<a name="Onpattro.3"></a>Onpattro (patisiran) [product monograph]. Oakville, Ontario, Canada: Innomar-Strategies; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118739 Version 45.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
